Biological and Immunomodulatory Effect of Hemoadsorption With Macroporous Resin Cartridges in Septic Shock and Refractory Septic Shock Two Parallel Open-label Randomized Pilot Trials.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- A more desirable overall outcome category in a pre-specified hierarchical ordinal varibles system ("DOOR"; Evans 2015; Pocock 2012).
研究概览
简要总结
Septic shock is the most severe form of sepsis and continues to carry an in-hospital mortality of between 30% and 50% despite advances in compliance with the Surviving Sepsis Campaign care bundles.
The pathophysiology of septic shock is dominated by an uncontrolled immuno-inflammatory response with massive release of mediators, pro- and anti-inflammatory cytokines5, DAMPs (damage-associated molecular patterns) and PAMPs (pathogen-associated molecular patterns), producing vasoplegia, endothelial dysfunction, glycocalyx damage and, in many patients, a subsequent immunoparalysis phase that increases the risk of nosocomial infections and late mortality.
Endothelial damage and glycocalyx degradation are central elements in the pathophysiology of septic shock. The endothelial glycocalyx, a layer of proteoglycans and glycosaminoglycans approximately 0.5 µm thick on the luminal surface of the endothelium, regulates vascular permeability, leukocyte adhesion and the inflammatory response. During sepsis, the release of metalloproteinases, heparanase and other inflammatory mediators causes the shedding of syndecan-1, heparan sulfate and other glycocalyx molecules into the circulation. This process is associated with increased capillary permeability, interstitial edema, third-space fluid leakage, and progression to multiorgan failure. Elevated plasma syndecan-1 levels correlate with greater severity of septic shock, development of acute respiratory distress syndrome (ARDS), extrapulmonary organ dysfunction, and mortality. In parallel, the release of angiopoietin-2 by activated endothelial cells antagonizes Tie2 signaling, destabilizes the endothelial barrier and amplifies vascular dysfunction.
Selective modulation of the immune response through extracorporeal adsorption of medium-sized mediators (5-60 kDa) is an adjunctive strategy whose biological rationale is well established and whose hemodynamic effect has been described by multiple authors. The HA380 HA cartridge (Jafron Biomedical), specifically, uses a synthetic neutral macroporous polymer resin with high affinity for cytokines in the 10-60 kDa range, especially IL-6, TNF-α, IL-8 and IL-10. The device is connected to an extracorporeal therapy circuit (in this protocol, always integrated into a continuous renal replacement therapy [CRRT] circuit) and operates for 4-6 hours per cartridge. Removal of proinflammatory cytokines (IL-6, TNF-α, IL-8) with HA380 also aims to reduce their effect on endothelial damage, and recent studies with other cytokine adsorbents have demonstrated the ability to remove circulating angiopoietin-2. Although the specific literature on the effect of HA380 on recovery of glycocalyx integrity is limited, reducing the burden of cytokines and endotoxic mediators could attenuate the glycocalyx degradation cascade and contribute to the hemodynamic stabilization observed in clinical studies. This mechanism provides an additional biological rationale for assessing biomarkers of endothelial dysfunction (angiopoietin-2, syndecan-1, soluble thrombomodulin) as secondary variables in the present study.
Within the spectrum of septic shock, this protocol distinguishes two clinically and biologically relevant severity strata: 1) established septic shock as per Sepsis-3 criteria who, despite requiring vasopressor support and showing hyperlactatemia, do not meet the thresholds of refractoriness. 2) refractory septic shock, a particularly severe subgroup in which standard resuscitation measures-guided fluid therapy, vasopressors, source control, early antibiotic therapy, and hydrocortisone-are insufficient to reverse tissue hypoperfusion and progressive organ dysfunction.
Primary objective To establish whether HA380 hemoadsorption yields a more desirable overall outcome than concurrent standard of care, within each severity stratum, using a pre-specified hierarchical ordinal DOOR endpoint.
详细描述
2. Background and rationale 2.1. The clinical problem: septic shock and its refractory form Septic shock is the most severe form of sepsis and continues to carry an in-hospital mortality of between 30% and 50% despite advances in compliance with the Surviving Sepsis Campaign care bundles1. Within the spectrum of septic shock, this protocol distinguishes two clinically and biologically relevant severity strata.
The first stratum comprises patients with established septic shock as per Sepsis-3 criteria who, despite requiring vasopressor support and showing hyperlactatemia, do not meet the thresholds of refractoriness. This intermediate-severity population, proposed for inclusion to characterize whether the magnitude of the biological effect of hemoadsorption depends on the baseline inflammatory burden, is expected to present a lower circulating cytokine load at baseline than the refractory stratum.
The second stratum comprises refractory septic shock, a particularly severe subgroup in which standard resuscitation measures-guided fluid therapy, vasopressors, source control, early antibiotic therapy, and hydrocortisone-are insufficient to reverse tissue hypoperfusion and progressive organ dysfunction.
Until 2026 the definition of refractory septic shock was variable and operationally heterogeneous2, which hampered comparison across studies. Two consensus statements published in 2026 now provide a reference for defining it reproducibly:
- A recent international Delphi consensus from the SCCM/ESICM societies3 defines refractory septic shock as persistently elevated lactate concentrations and/or prolonged capillary refill time in a fluid-unresponsive septic shock patient requiring a norepinephrine equivalent ≥ 0.5 µg/kg/min and in whom clinical ultrasound has ruled out a mixed-shock component.
- The Delphi consensus of the Spanish Society of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC)4 concludes that refractory septic shock is a clinical entity with persistent hypotension and signs of global hypoperfusion for more than one hour despite optimized initial treatment-including the use of hydrocortisone-with elevated lactate as a marker of hypoperfusion, and that requires advanced hemodynamic monitoring and echocardiography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All of the following:
- •Age ≥ 18 years.
- •Diagnosis of septic shock per Sepsis-3, with an identified or highly probable infectious focus.
- •Meeting the operational definition of one of the two severity strata (SS or RSS) detailed in 6.
- •Onset of septic shock within the last 24 hours (applied identically to both strata).
- •Large-bore vascular access.
- •Informed consent signed by the legal representative.
排除标准
- •Decision to limit life-sustaining therapy made or anticipated within the next 48 hours.
- •Absolute contraindication to anticoagulation with heparin and citrate.
- •Predominant non-septic shock (hemorrhagic, primary cardiogenic, obstructive).
- •Ongoing pregnancy.
- •Platelet count < 20,000/µL.
- •Significant pharmacological immunosuppression: chronic corticosteroids at doses > 20 mg/day prednisone equivalent, biologics within the last 6 months, cytotoxic chemotherapy within the last 4 weeks.
- •Solid organ or hematopoietic stem cell transplantation.
- •Concurrent participation in another clinical trial.
结局指标
主要结局
A more desirable overall outcome category in a pre-specified hierarchical ordinal varibles system ("DOOR"; Evans 2015; Pocock 2012).
时间窗: 30 days
To establish whether HA380 hemoadsorption yields a more desirable overall outcome than concurrent standard of care, within each severity stratum, using a pre-specified hierarchical ordinal DOOR endpoint Level and Definition (assessed within each severity stratum) 5. (most desirable): Alive at day 30 + relevant decrease in all 4 components (IL-6, VIS, SOFA-2, lactate)\* at T6 4. Alive at D30 + relevant decrease in 3 of the 4 components at T6 3. Alive at D30 + relevant decrease in 2 of the 4 components at T6 2. Alive at D30 + decrease in 0-1 of the 4 components at T6 1. (least desirable): Death by D30, irrespective of any biological change \* IL-6, reduction ≥ 30% from T0; VIS, any reduction (\> 0) from T0; SOFA-2, reduction ≥ 2 points from T0; and serum lactate, a value \< 2 mmol/L at T6 or a reduction ≥ 10% from T0. A component that cannot be evaluated in a day-30 survivor because of a missing T6 measurement is conservatively counted as 'no decrease'
次要结局
- Biological endpoints(72 hours)
- Exploratory physiological variables(72 hours)
研究者
Miguel Sanchez Garcia
Emeritus Director Critical Care Department
Hospital San Carlos, Madrid
